We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Biomarkers Predict Kidney Problems After Cardiac Surgery

By LabMedica International staff writers
Posted on 13 Mar 2012
Blood and urine markers can indicate which patients with an abrupt kidney injury following heart surgery will experience progressive kidney problems.

Until now, doctors have not been able to determine which cases of acute kidney injury (AKI) that develop after heart surgery will worsen so testing for these markers soon after surgery could help doctors protect the health of patients' kidneys. More...


At Yale University School of Medicine (New Haven, CT, USA) investigators found that the presence of certain markers on the day that AKI is diagnosed can indicate structural injury to the kidneys that will likely cause patients to experience progressive problems. They prospectively enrolled 1,219 adults undergoing cardiac surgery (coronary artery bypass grafting or valve surgery) who were at high risk for AKI at six academic medical centers in North America between July of 2007 and December of 2009. Urine and plasma specimens collected preoperatively and daily for up to five postoperative days.

High urinary interleukin-18 (IL-18) and the albumin-to-creatinine ratio (ACR) increased patients' risk of experiencing persistent AKI by approximately three-fold, while high blood levels of a protein called neutrophil gelatinase-associated lipocalin (NGAL) increased their risk by more than seven-fold. Urine IL-18 and NGAL were measured with the ARCHITECT assay (Abbott Diagnostics, Abbott Park, IL, USA). Plasma NGAL was measured through the Triage NGAL immunoassay in conjunction with the TriageMeter (Biosite Inc., San Diego, CA, USA).

The authors concluded that urinary IL-18, ACR, and plasma NGAL measurement at the time of clinical creatinine increase forecasted the progression of AKI in adults after cardiac surgery. Chirag Parikh, MD, PhD, a lead author of the study said, "Our multicenter study is the largest acute kidney injury biomarker study performed to date in adults, and it strengthens the new paradigm that assessing structural injury at the time of clinical diagnosis with urine or blood markers of kidney injury can yield important prognostic information." The study was published online on March 1, 2012, in the Journal of the American Society Nephrology.

Related Links:

Yale University School of Medicine
Abbott Diagnostics
Biosite Inc



Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Prefilled Tubes
Prefilled 5.0ml Tubes
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.